Amol Akhade

Employment

• Fortis Hospital senior consultant
  2025 - Present

Education

• Tata Memorial Hospital DM
  2007 - 2010

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income Countries
  JCO Global Oncology 2026 DOI: 10.1200/GO-25-00361
  +Save
• Subcutaneous immunotherapy—a wolf in sheep's clothing?
  The Lancet Oncology 2025 DOI: 10.1016/s1470-2045(25)00615-1
  +Save
• Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies
  European Journal of Cancer 2025 DOI: 10.1016/j.ejca.2025.115564
  +Save
• Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)
  South Asian Journal of Cancer 2025 DOI: 10.1055/s-0044-1791768
  +Save
• Geriatric oncology in LMICs: it is time to mature
  BMJ Oncology 2024 DOI: 10.1136/bmjonc-2024-000537
  +Save
• Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities
  JCO Global Oncology 2023 DOI: 10.1200/GO.23.00344
  +Save
• Highlights from the Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th–18th September, Mumbai, India
  ecancermedicalscience 2022 DOI: 10.3332/ecancer.2022.1465
  +Save
• CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
  ecancermedicalscience 2022 DOI: 10.3332/ecancer.2022.ed124
  +Save
• Cancer research in lower- and middle-income countries (LMICs)
  Indian Journal of Cancer 2022 DOI: 10.4103/ijc.ijc_662_22
  +Save
• Global consequences of the US FDA's accelerated approval of cancer drugs
  The Lancet Oncology 2022 DOI: 10.1016/s1470-2045(21)00709-9
  +Save